SAN FRANCISCO--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from a Phase 1 clinical trial (GS-US-279-0110) of GS-6615, an investigational, selective late sodium current inhibitor, showing a shortening of the QTc interval (the time interval between the start of the Q-wave and end of the T-wave in the heart’s electrical cycle) in patients with long QT-3 (LQT3) syndrome. LQT3 is a genetic disorder that prolongs the heart’s QTc interval and can cause life-threatening cardiac arrhythmias (abnormal heartbeats). Results from this study (Abstract #AB34-05) will be presented today in San Francisco at the annual meeting of the Heart Rhythm Society.
Help employers find you! Check out all the jobs and post your resume.
